Exelixis, Inc. (EXEL) Stock Rating Reaffirmed by Stifel Nicolaus
Exelixis, Inc. (NASDAQ:EXEL)‘s stock had its “hold” rating reiterated by research analysts at Stifel Nicolaus in a note issued to investors on Thursday. They presently have a $26.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ price target indicates a potential upside of 1.33% from the company’s current price.
EXEL has been the topic of a number of other reports. BidaskClub upgraded shares of Exelixis from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Cowen and Company reiterated an “outperform” rating on shares of Exelixis in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $28.00 price target on the stock in a research note on Tuesday, July 4th. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Thursday, July 27th. Finally, SunTrust Banks, Inc. initiated coverage on shares of Exelixis in a research note on Thursday, July 13th. They set a “buy” rating and a $33.00 price target on the stock. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $25.57.
Shares of Exelixis (NASDAQ EXEL) traded down 8.91% on Thursday, reaching $25.66. 10,066,618 shares of the company’s stock traded hands. The firm’s 50 day moving average is $27.17 and its 200 day moving average is $23.21. Exelixis has a 52 week low of $10.04 and a 52 week high of $29.50. The firm has a market capitalization of $7.54 billion, a P/E ratio of 129.60 and a beta of 1.97.
Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. The firm had revenue of $99.01 million for the quarter, compared to analyst estimates of $85.27 million. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. Exelixis’s revenue was up 173.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.15) EPS. Analysts expect that Exelixis will post $0.26 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in EXEL. First Quadrant L P CA acquired a new position in shares of Exelixis during the second quarter worth about $144,000. Meeder Asset Management Inc. acquired a new position in shares of Exelixis during the first quarter worth about $170,000. Atlantic Trust Group LLC acquired a new position in shares of Exelixis during the first quarter worth about $216,000. Wetherby Asset Management Inc. acquired a new position in shares of Exelixis during the second quarter worth about $218,000. Finally, Caxton Associates LP acquired a new position in shares of Exelixis during the second quarter worth about $227,000. 79.20% of the stock is owned by institutional investors and hedge funds.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.